SCHEMBL2324149

SCHEMBL2324149

CNC(=O)N1CC=CCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.54
NPC1 O15118 2/20 0.51
LMNA P02545 2/20 0.51
RAB9A P51151 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
DPP7 Q9UHL4 4/20 0.44
DPP4 P27487 4/20 0.44
DPP8 Q6V1X1 2/20 0.44
CTSK P43235 1/20 0.39
AKR1C3 P42330 1/20 0.38
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
BACE1 P56817 2/20 0.34
DPP9 Q86TI2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19027439 0.84
SCHEMBL4204778 0.81
SCHEMBL29135819 0.79 KMT2A (0.59) NPC1LMNARAB9ATDP1HPGD
SCHEMBL5255379 0.79 LMNA (0.47) POLBNPC1LMNARAB9ATDP1
SCHEMBL18129500 0.79 SMN1; SMN2 (0.49) NPC1LMNARAB9ATDP1HPGD
SCHEMBL4030616 0.76 POLB (0.68) POLBNPC1RAB9ATDP1SMN1; SMN2
SCHEMBL1026847 0.76
SCHEMBL2330308 0.75 DPP7 (0.44) NPC1LMNARAB9ATDP1HPGD
SCHEMBL28353718 0.75 DPP7 (0.46) NPC1LMNARAB9ATDP1HPGD
SCHEMBL18129800 0.74 DPP7 (0.51) POLBNPC1LMNARAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230168-A1 AZASPIRO WRN INHIBITORS GILEAD SCIENCES, INC. 2025-07-17 US disclosed
WO-2022257894-A1 P300 INHIBITOR AND PHARMACEUTICAL USE THEREOF 贝达药业股份有限公司 2022-12-15 WO disclosed
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2019-03-26 US disclosed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US disclosed
EP-2356116-A1 SUBSTITUTED PYRROLOÝ2,3-B¨-PYRIDINES AND-PYRAZINES OSI Pharmaceuticals, Inc. (US) 2011-08-17 EP disclosed
US-5373000-A Antibacterial agent against both grampositive and gramnegative bacterias EISAI CO., LTD. (JP) 1994-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230168-A1 AZASPIRO WRN INHIBITORS WRN, RECQL, BLM POLB 61/4885NPC1 3201/4885LMNA 938/4885
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TANK, NFKBIA, TBK1 POLB 2305/4885NPC1 4048/4885LMNA 2773/4885
US-10239873-B2 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same NFKBIA, TANK, TBK1 POLB 2028/4885NPC1 4107/4885LMNA 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.